UBS AM
COGT icon

UBS AM’s Cogent Biosciences COGT Stock Holding History

UBS AM’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.1M Buy
209,402
+43,892
+27% +$1.54M ﹤0.01% 1367
2026
Q1 		$6.37M Buy
165,510
+1,370
+0.8% +$50.6K ﹤0.01% 1442
2025
Q4 		$5.83M Buy
164,140
+21,186
+15% +$596K ﹤0.01% 1382
2025
Q3 		$2.05M Sell
142,954
-64,244
-31% -$761K ﹤0.01% 1737
2025
Q2 		$1.49M Buy
207,198
+58,918
+40% +$327K ﹤0.01% 2273
2025
Q1 		$888K Buy
148,280
+12,676
+9% +$99.4K ﹤0.01% 2360
2024
Q4 		$1.06M Buy
135,604
+17,741
+15% +$177K ﹤0.01% 2334
2024
Q3 		$1.27M Sell
117,863
-8,354
-7% -$81.3K ﹤0.01% 2273
2024
Q2 		$1.06M Buy
126,217
+56,660
+81% +$430K ﹤0.01% 2344
2024
Q1 		$467K Buy
69,557
+10,000
+17% +$61.8K ﹤0.01% 2307
2023
Q4 		$350K Buy
59,557
+7,900
+15% +$60.5K ﹤0.01% 2393
2023
Q3 		$504K Buy
51,657
+29,457
+133% +$349K ﹤0.01% 2296
2023
Q2 		$240K Hold
22,200
– – ﹤0.01% 2532
2023
Q1 		$240K Hold
22,200
– – ﹤0.01% 2532
2022
Q4 		$257K Buy
+22,200
New +$275K ﹤0.01% 2374

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS AM's COGT Position: Q2 2026 in Review

UBS AM increased its Cogent Biosciences (COGT) stake by 27% in Q2 2026, buying an estimated $1.54M and bringing the position to 209,402 shares worth $8.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1367.

UBS AM first reported a position in COGT in Q4 2022 and has held it in 15 quarters since. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • UBS AM held 209,402 shares of Cogent Biosciences worth $8.1M as of Q2 2026.
  • UBS AM bought 43,892 Cogent Biosciences shares in Q2 2026, an estimated $1.54M.
  • Cogent Biosciences made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1367 holding.
  • UBS AM first reported a position in Cogent Biosciences in Q4 2022 and has held it in 15 quarters since.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.